Jin Li-Qun, Xu Zhe-Wen, Zhang Bo, Yi Ming, Weng Chun-Yue, Lin Shan, Wu Hui, Qin Xiang-Tian, Xu Feng, Teng Yi, Yuan Shui-Jin, Liu Zhi-Qiang, Zheng Yu-Guo
Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, 310014, China.
HuaDong Medicine (Hangzhou) Bailing Biological Technology Co., Ltd, Hangzhou, 311220, China.
AMB Express. 2020 Jun 3;10(1):105. doi: 10.1186/s13568-020-01039-x.
Ophiocordyceps sinensis has been used as a traditional medicine or healthy food in China for thousands of years. Hirsutella sinensis was reported as the only correct anamorph of O. sinensis. It is reported that the laboratory-grown H. sinensis mycelium has similar clinical efficacy and less associated toxicity compared to the wild O. sinensis. The research of the H. sinensis is becoming more and more important and urgent. To gain deeper insight into the biological and pharmacological mechanisms, we sequenced the genome of H. sinensis. The genome of H. sinensis (102.72 Mb) was obtained for the first time, with > 99% coverage. 10,200 protein-encoding genes were predicted based on the genome sequence. A detailed secondary metabolism analysis and structure verification of the main ingredients were performed, and the biosynthesis pathways of seven ingredients (mannitol, cordycepin, purine nucleotides, pyrimidine nucleotides, unsaturated fatty acid, cordyceps polysaccharide and sphingolipid) were predicted and drawn. Furthermore, infection process and mechanism of H. sinensis were studied and elaborated in this article. The enzymes involved in the infection mechanism were also predicted, cloned and expressed to verify the mechanism. The genes and proteins were predicted and annotated based on the genome sequence. The pathways of several active components in H. sinensis were predicted and key enzymes were confirmed. The work presented here would improve the understanding of the genetic basis of this organism, and contribute to further research, production and application of H. sinensis.
在中国,冬虫夏草作为传统药物或健康食品已被使用了数千年。中华被毛孢被报道为冬虫夏草唯一正确的无性型。据报道,与野生冬虫夏草相比,实验室培养的中华被毛孢菌丝体具有相似的临床疗效且毒性较小。对中华被毛孢的研究变得越来越重要和紧迫。为了更深入地了解其生物学和药理机制,我们对中华被毛孢的基因组进行了测序。首次获得了中华被毛孢的基因组(102.72 Mb),覆盖率超过99%。基于基因组序列预测了10200个蛋白质编码基因。对主要成分进行了详细的次生代谢分析和结构验证,并预测和绘制了七种成分(甘露醇、虫草素、嘌呤核苷酸、嘧啶核苷酸、不饱和脂肪酸、虫草多糖和鞘脂)的生物合成途径。此外,本文还研究并阐述了中华被毛孢的感染过程和机制。对参与感染机制的酶也进行了预测、克隆和表达以验证该机制。基于基因组序列对基因和蛋白质进行了预测和注释。预测了中华被毛孢中几种活性成分的途径并确认了关键酶。本文所做的工作将增进对该生物体遗传基础的理解,并有助于中华被毛孢的进一步研究、生产和应用。